

American College of Rheumatology 2010 Recommendations for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis

JENNIFER M. GROSSMAN,¹ REBECCA GORDON,² VEENA K. RANGANATH,¹ CHAD DEAL,³
LIRON CAPLAN,⁴ WEILING CHEN,¹ JEFFREY R. CURTIS,⁵ DANIEL E. FURST,¹ MAUREEN McMAHON,¹
NIVEDITA M. PATKAR,⁵ ELIZABETH VOLKMANN,¹ AND KENNETH G. SAAG⁵

Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide guidance for particular patterns of practice and not to dictate the care of a particular patient. The ACR considers adherence to these guidelines and recommendations to be voluntary, with the ultimate determination regarding their application to be made by the physician in light of each patient's individual circumstances. Guidelines and recommendations are intended to promote beneficial or desirable outcomes but cannot guarantee any specific outcome. Guidelines and recommendations developed or endorsed by the ACR are subject to periodic revision as warranted by the evolution of medical knowledge, technology, and practice.

These recommendations have been reviewed and endorsed by the American Society for Bone and Mineral Research.

INTRODUCTION

Although glucocorticoids may effectively be used in the management of many inflammatory conditions, their use is

associated with significant morbidity and mortality. Osteoporosis, with resultant fractures, constitutes one of these morbid complications and is associated with significant pain and disability. A rapid decline in bone mineral density (BMD) begins within the first 3 months of glucocorticoid use and peaks at 6 months, followed by a slower,

¹Jennifer M. Grossman, MD, Veena K. Ranganath, MD, Weiling Chen, MA, Daniel E. Furst, MD, Maureen McMahon, MD, MSc, Elizabeth Volkmann, MD: University of California, Los Angeles; ²Rebecca Gordon, MD: VA Greater Los Angeles Healthcare System and University of California, Los Angeles; ³Chad Deal, MD: Cleveland Clinic, Cleveland, Ohio; ⁴Liron Caplan, MD: University of Colorado, Denver; ⁵Jeffrey R. Curtis, MD, MPH, Nivedita M. Patkar, MD, MSPH, Kenneth G. Saag, MD, MSc: University of Alabama, Birmingham.

Dr. Deal has received consultant fees, speaking fees, and/or honoraria (more than \$10,000 each) from Lilly, Amgen, and Genentech. Dr. Curtis has received consultant fees, speaking fees, and/or honoraria (less than \$10,000 each) from Eli Lilly and Procter & Gamble, and (more than \$10,000 each) from Novartis, Amgen, Roche/Genentech, and Merck. Dr. Saag has received consultant fees, speaking fees, and/or honoraria (less than \$10,000 each) from Merck, Lilly, Novartis, Aventis, Genentech, AstraZeneca, Pfizer, and Horizon.

Members of the Core Executive Panel: Jennifer M. Grossman, MD, Veena K. Ranganath, MD, Weiling Chen, MA, Daniel E. Furst, MD, Maureen McMahon, MD, MSc, Elizabeth Volkmann, MD, Rebecca Gordon, MD, Kenneth G. Saag, MD, MSc, Jeffrey R. Curtis, MD, MPH, Nivedita M. Patkar, Liron Caplan, MD.

Members of the Task Force Panel: Robert Adler, MD (McGuire VA Medical Center, Richmond, VA), Gary Bryant,

MD (University of Minnesota, Minneapolis), Cathleen Colton-Emeric, MD, MHSc (Duke University, Durham, NC), Chad Deal, MD (Cleveland Clinic, Cleveland, OH), Joseph Flood, MD (Musculoskeletal Medical Specialists, Columbus, OH), Theodore Hahn, MD (VA Greater Los Angeles Healthcare System GRECC and University of California, Los Angeles), Amye Leong, MBA (Healthy Motivation, Santa Barbara, CA), Michael Maricic, MD (University of Arizona, Tucson), Anthony Sebba, MD (University of South Florida, Tampa), Stuart Silverman, MD (University of California, Los Angeles).

Members of the Expert Advisory Panel: Johannes W. J. Bijlsma, MD (University of Utrecht, Utrecht, The Netherlands), Chad Deal, MD (Cleveland Clinic, Cleveland, OH), Nancy Lane, MD (University of California, Davis), Marc Hochberg, MD, MPH (University of Maryland, Baltimore), Willem Lems, MD (Vrije Universiteit Medical Centre, Amsterdam, The Netherlands), Catherine MacLean, MD, PhD (WellPoint, Inc., Thousand Oaks, CA).

The American College of Rheumatology is an independent professional, medical, and scientific society which does not guarantee, warrant, or endorse any commercial product or service.

Address correspondence to Jennifer M. Grossman, MD, UCLA, 1000 Veteran Avenue, Room 32-59, Rehabilitation Building, Los Angeles, CA 90095. E-mail: jgrossman@mednet.ucla.edu.

Submitted for publication December 4, 2009; accepted in revised form July 6, 2010.

steady loss with continued use (1). An increased risk of both vertebral and nonvertebral fractures has been reported with dosages of prednisolone or equivalent as low as 2.5–7.5 mg daily, and this risk may relate more strongly to daily rather than to cumulative doses of glucocorticoids (2,3). However, there has been some controversy regarding the dose at which an increased risk of fracture occurs, as some smaller studies have found no appreciable decline in bone density with mean daily 8.0 mg dosages of prednisone (4), or prednisone <5 mg/day (5). In a large meta-analysis, prior and current use of oral glucocorticoids increased the risk of any type of fracture, with no significant difference in relative risk between men and women (6).

A number of treatment options for the prevention and management of glucocorticoid-induced osteoporosis (GIOP) are now available. Both alendronate and risedronate improve BMD and decrease the risk of vertebral fractures in patients treated with glucocorticoids (7–10). More recently, teriparatide and zoledronic acid have demonstrated efficacy in the management of GIOP with increases in BMD above that of the comparator arms, which employed alendronate and risedronate, respectively (11,12).

Despite the availability of therapies to reduce the risk of fractures, many patients receiving long-term glucocorticoid therapy do not receive any interventions to prevent or treat osteoporosis. In some populations, less than one-third received BMD testing or had documented use of calcium and vitamin D supplementation (13–15). Similarly, the use of bisphosphonate therapy is low, particularly among men and younger women (14–16).

In 2001, the American College of Rheumatology (ACR) published their Recommendations for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis (17). Since their development, additional therapies and new data on therapies included in the previous recommendations have become available. Updated approaches to identify patients at highest risk for fracture have also been developed. Bone density alone may not be the sole reliable diagnostic approach for some patients receiving glucocorticoids, since fracture in patients receiving glucocorticoids may occur independently of a decline in bone mass (6). In 2008, the National Osteoporosis Foundation incorporated the 10-year absolute probability of fracture calculated by the FRAX tool (18) into their guidelines for the treatment and prevention of osteoporosis and included glucocorticoid use as a clinical risk factor (19). Furthermore, the methodology for guideline development has evolved since 2001, when a more informal consensus approach was used (17). Collectively, these factors support the need for a reappraisal and update of the 2001 recommendations.

In order to revise these recommendations on behalf of the ACR, a primary Core Executive Panel utilized the Research and Development/University of California at Los Angeles (RAND/UCLA) method, the assistance of 2 expert panels (the Expert Advisory Panel to frame the development of the recommendations and the Task Force Panel to vote on the specific recommendations), and a systematic literature review (methodology described in detail below). The 2010 recommendations are reported below.

Since even rigorously developed guidelines have limi-




Figure 1. Groups responsible for each component of the glucocorticoid-induced osteoporosis (GIOP) recommendations development. RAND/UCLA = Research and Development/University of California at Los Angeles.

tations in informing individual patient care, we selected the term “recommendations” to describe this work. These recommendations should not supplant clinical judgment, nor are they intended to serve as indicators of quality of care. Rather, they provide expert opinion and evidence-based guidance on the prevention and treatment of GIOP.

MATERIALS AND METHODS

The methods used to update the ACR GIOP recommendations followed the same general principles that were employed in developing the ACR recommendations for the use of biologic and nonbiologic disease-modifying antirheumatic drugs in rheumatoid arthritis (20). Figure 1 illustrates this process, which is described in more detail below.

Topic development. To update the recommendations, we incorporated the existing concepts from the 2001 guidelines and also refined the scope of the project. We convened an Expert Advisory Panel comprised of 6 rheumatologists with expertise in GIOP, including guideline development. To narrow the scope of the work and because of limited available data in certain areas, the Expert Advisory Panel set the following restrictions for our recommendations: first, the inclusion of medications approved for use in the treatment of osteoporosis in the US,

Canada, or the European Union; second, the exclusion of GIOP in the transplant populations; third, the exclusion of GIOP in the pediatric population; and fourth, the exclusion of inhaled glucocorticoids.

We next constructed the clinical scenarios that would be used by the Task Force Panel to develop the recommendations. An example of a clinical scenario was “In a high risk patient starting glucocorticoids with an anticipated duration of >3 months or on long-term therapy, which of the following medications would be appropriate to use based on a range of glucocorticoid doses?” followed by the list of all potential medications to treat or prevent GIOP. The complete set of scenarios is available in the Supplementary Appendix (available in the online version of this article at [http://onlinelibrary.wiley.com/journal/10.1002/\(ISSN\)2151-4658](http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2151-4658)).

In an effort to make the process of evaluating the clinical scenarios both feasible and clinically meaningful, we collapsed multiple risk factors for fractures into 3 fracture risk categories: high, medium, and low risk, guided in part by the FRAX risk assessment tool (21). The FRAX tool uses updated, evidence-based estimates of absolute fracture risk and was created for the purpose of quantitatively integrating numerous clinical factors into a clinically useful risk prediction model (22). To determine the cut points for each of the risk categories, the Expert Advisory Panel rated 48 patient examples that were derived by permuting each of the following 4 variables in all possible combinations: sex, age (55, 65, and 75 years of age), race/ethnicity (white and African American), femoral neck density T scores (0.0, -1.0, -1.5, -2.0, and -2.5), and obtaining the corresponding major osteoporotic and hip fracture FRAX scores. Glucocorticoid use was assumed to be present for all subjects. An average body mass index (BMI) of 25 kg/m² was also assumed. The remaining variables used in the calculation of the FRAX score (secondary osteoporosis, prior fracture, chronic alcohol use, current smoker, rheumatoid arthritis, and parental history of a hip fracture) were presumed absent. Because the FRAX scores for the race/ethnicity categories of Hispanic and Asian fell consistently between the scores for African American and white, the Hispanic and Asian categories were not used in the rating process, which included only the more extreme categories of African American and white. All of these modifications and compressions were done to reduce the number of scenarios to a total that was manageable by the Task Force Panel and were clinically meaningful as well.

The Expert Advisory Panel recommended the use of either the actual FRAX tool to define low-, medium-, and high-risk patients or the reliance by clinicians upon examples of patients that were typical of low-, medium-, and high-risk categories (as shown in Figure 2). Using the FRAX calculator, the Expert Advisory Panel defined a 10-year risk of a major osteoporotic fracture of 10% or less as low risk, 10–20% as medium risk, and greater than 20% or a T score of less than or equal to -2.5 or a history of a fragility fracture as high risk (which is the threshold for cost-effective treatment recommended by the National Osteoporosis Foundation) (22).

Because the FRAX equations are dynamic and will likely be refined over time (changes occurred in October




Figure 2. Typical examples of postmenopausal women and men age ≥ 50 years with a history of glucocorticoid use at high, medium, and low risk of fracture in the absence of other risk factors in **A**, white women, **B**, African American women, **C**, white men, and **D**, African American men. High-, medium-, and low-risk patient classification based on an approximation of FRAX 3.0 using age, sex, race, T score, and the presence of glucocorticoids for the calculation, with all other risk factors in the FRAX calculation absent. For example, a 65-year-old white man receiving glucocorticoids with a T score of -1.5 at the total hip would be considered a medium-risk patient if other risk factors listed in Table 1 were absent. Recommendations for this type of medium-risk patient are found in Tables 2, 3, and 4.

2008 [FRAX version 2.0] and September 2009 [FRAX version 3.0]) and because the equations have not been validated specifically for glucocorticoid-treated cohorts, the Expert Advisory Panel did not want to limit the GIOP recommendations by requiring the use of FRAX. Moreover, the same panel recognized that health care providers may confront logistical limitations in calculating a FRAX score within the clinic setting. Therefore, Figures 2A–D were constructed to provide clinicians with examples of typical patients to “match” their individual patient with the most closely fitting category. Determining risk category for other ethnic/racial groups using typical patient examples may be more complicated because of limited data. A study using Medicare claims data found that osteoporosis and fracture risk prevalence were 2-times higher for

Table 1. Clinical factors that may shift an individual to a greater risk category for glucocorticoid-induced osteoporosis

Low body mass index Parental history of hip fracture Current smoking ≥ 3 alcoholic drinks per day Higher daily glucocorticoid dose Higher cumulative glucocorticoid dose Intravenous pulse glucocorticoid usage Declining central bone mineral density measurement that exceeds the least significant change
--

whites, Asian Americans, and Hispanic Americans than African Americans (23). In postmenopausal women in the US, African Americans have the highest BMD and lowest fracture risk, Hispanics and whites have a lower BMD and highest fracture risk, and Asians have the lowest BMD but a fracture risk that is similar to African Americans (24).

Fracture risk in the “typical patient” (Figures 2A–D) may be increased in patients who have additional risk factors that were presumed to be absent in our scenarios (such as low BMI, parental history of hip fracture, current smoking, and consuming three or more alcoholic drinks per day). Since FRAX uses an average glucocorticoid dose to calculate the 10-year probability of a major osteoporotic fracture, those receiving higher doses are likely to have a greater absolute fracture risk than estimated by the FRAX. Higher cumulative glucocorticoid dose (3) and intravenous pulse glucocorticoids may also increase the risk of fractures (25,26). A declining central BMD measurement that exceeds the least significant change may be another reason that clinicians would move a patient to a higher risk category. These factors (Table 1) need to be considered in the health care provider’s assessment of the patient and may shift an individual into a greater risk category (low→medium, or medium→high).

Systematic literature review. We conducted a systematic review of the therapies currently approved for the treatment of postmenopausal osteoporosis or GIOP in the US, Canada, or the European Union as well as calcium, vitamin D, and testosterone. Articles were limited to randomized clinical trials (RCTs) or controlled clinical trials (CCTs) of human subjects reported in English with an available abstract. The study duration must have been ≥ 6 months and all subjects were required to have incident or prevalent glucocorticoid use. With the assistance of a professional research librarian, we replicated the search strategy employed in the Comparative Effectiveness of Treatments for Low Bone Density (including Osteoporosis) Report prepared for the Agency for Health Care Research and Quality for alendronate, risedronate, ibandronate, zoledronic acid, calcitonin, teriparatide, and strontium (27). We searched Medline (through PubMed) by applying MeSH headings and relevant keywords with references from January 1966 through August 28, 2008 using Cochrane’s Highly Selective Search Strategy (28) to improve the specificity of the search. Searches for calcium, vitamin D, estrogen, and

testosterone were performed in a similar manner, but limited to GIOP. Using the Cochrane Handbook’s guidance, we also conducted similar searches of EMBase in CENTRAL (28). Details of the search strategy are listed in Supplementary Appendix A (available in the online version of this article at [http://onlinelibrary.wiley.com/journal/10.1002/\(ISSN\)2151-4658](http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2151-4658)). Additionally, abstracts from the 2007–2008 ACR Annual Scientific Meeting, European League Against Rheumatism annual European Congress of Rheumatology, Annual Meeting of the American Society for Bone and Mineral Research, and European Calcific Tissue Society European Symposium on Calcified Tissues were manually searched for relevant RCTs. The Core Executive Panel and Expert Advisory Panel members contributed expert-identified studies to complete the search.

Three reviewers screened each title and abstract for relevance to the specific aims of the predefined inclusion criteria for the evidence report. This process resulted in a total of 53 articles (7–9,11,12,29–76) meeting inclusion criteria and these publications formed the basis of the evidence report. Accepted articles were then reviewed independently by 2 of the 7 reviewers (RG, MM, EV, NMP, LC, VKR, JMG), and the consensus on the relevant data was entered into a standardized data abstraction form. For each RCT and CCT, study characteristics, sample size, outcomes, and quality assessment (calculated using the 5-point Jadad score) (77) were reported in tabular form. Jadad scores are based on a 5-point scale, with higher scores suggesting higher-quality studies. The mean Jadad score for the 53 included articles was 2.44 (interquartile range 1–3). This score indicated that the articles as a whole were of only moderate quality. The principal investigator (JMG) adjudicated discrepant results. Relevant meta-analyses (78–84) were also described in the report.

The function of the evidence report was to provide the data for evaluation of clinical scenarios used to illustrate the key permutations of potential clinical interventions for the evaluation and management of GIOP. Some clinical scenarios, such as those involving repeat BMD testing, did not have RCT data as supportive evidence. In those situations, qualitative literature reviews and expert-identified articles were used to summarize existing evidence. This summarized data helped to guide the development of the clinical scenarios and formed the basis for the evidence report that was used in the next phase of the recommendations development.

RAND/UCLA Appropriateness Method used by the Task Force Panel. The RAND/UCLA Appropriateness Method (85–87), which incorporates elements of the nominal and Delphi method, was used to generate the recommendations presented in this report. The RAND/UCLA Appropriateness Method was developed to combine the best available scientific evidence with the collective judgment of experts to yield a statement regarding the appropriateness of a treatment based on patient-specific symptoms, medical history, and test results. The method combines a systematic review of the scientific literature with expert opinion and yields specific criteria of appropriateness that can be used as the basis for review criteria, practice guidelines, or both. This technique has previously




Figure 3. Approach to postmenopausal women and men age >50 years initiating or receiving glucocorticoid therapy. * = for low- and medium-risk patients, recommendations are for an anticipated or prevalent duration of ≥ 3 months of glucocorticoids.

been described as the best systematic method of combining expert opinion and evidence (88,89).

As the first step in this process, the Task Force Panel, which consisted of 10 individuals from the fields of rheumatology, endocrinology, and geriatrics, and a patient care advocate, received the evidence report and case scenarios. The Task Force Panel independently rated the appropriateness of the specific interventions within the context of the clinical scenarios with varying fracture risk, glucocorticoid dose, and duration. Instructions for grading scenarios and definitions of all variables were provided by e-mail and discussed during a conference call. The Task Force Panel was asked to use the evidence as summarized in the evidence report as well as their own clinical judgment to rate the appropriateness of employing a particular therapy in the context of each clinical scenarios using a 9-point Likert scale, where 1 = appropriate and 9 = not appropriate. Results from the first round of voting were tabulated and presented at a face-to-face panel meeting comprised of the Core Expert Panel and Task Force Panel. The summarized anonymous scores, including range and median as well as the panelist's own ranking, were provided to each voting member. Areas of discrepancy as well as areas of agreement were discussed and a second round of any-

mous voting by the Task Force Panel alone occurred using the same scale. Vitamin D and calcium were evaluated as additive therapy and testosterone and estrogen as primary therapy in hypogonadal patients. The results of the second round of voting determined the updated recommendations. The clinical scenarios specifically did not attempt to prioritize the use of one drug over another when both were deemed appropriate in a particular circumstance.

At the face-to-face meeting, additional questions related to risk factors for premenopausal patients arose that were not adequately addressed by the systematic review. Therefore, voting for premenopausal women and for men age <50 years without prior fragility fracture was deferred until an additional literature search to identify non-RCT/CCT studies had been performed and disseminated to panel members and discussed in a subsequent conference call.

Statistical analysis. Recommendations applying to individual scenarios were endorsed when the median score from the panelist voting fell in the 1 to 3 range and there was no disagreement. Disagreement was defined as 3 or more of the 10 voting panelists rating the scenario in the




Figure 4. Approach to premenopausal women and men age <50 years initiating or receiving glucocorticoid therapy. pred = prednisone.

middle or highest tertiles (i.e., 4 to 9). Only positive statements were included in the recommendations. Absence of any recommendation should not be construed to suggest that a treatment was inappropriate in particular settings; the absence of a recommendation generally implied only inadequate or conflicting evidence.

We used the AGREE instrument to help assure that the updated recommendations covered all the important domains and attributes (90). The AGREE instrument grades elements of validity and includes 6 sections: scope and purpose, stakeholder involvement, rigor of development, clarity and presentation, applicability, and editorial independence.

Rating the strength of evidence. The strength of evidence was graded using the methods reported by the American College of Cardiology (91) as follows: 1) for level of evidence A, data were derived from multiple RCTs or a meta-analysis, 2) for level B evidence, data were derived from a single RCT or nonrandomized study, and 3) for level C evidence, data were derived from consensus, expert opinion, or case series. Although few RCTs were performed exclusively in premenopausal patients, many studies did include premenopausal women as part of the overall cohort. These studies were therefore included when determining the evidence grade for recommendations for premenopausal women and men younger than age 50 years.

ACR review of recommendations. In addition to traditional manuscript review, a draft of the evidence report was submitted to the ACR Guidelines Subcommittee, ACR

Quality of Care Committee, and ACR Board of Directors for comments and recommendations, which were incorporated into the final recommendations.

RESULTS

The results of the modified RAND/UCLA method produced the recommendations shown below. Figures 3 and 4 represent proposed approaches to the management of GIOP. A synopsis of the recommendations are shown in the Supplementary Appendix entitled Clinician's Guide (available in the online version of this article at [http://onlinelibrary.wiley.com/journal/10.1002/\(ISSN\)2151-4658](http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2151-4658)).

Recommendations for assessment, counseling for lifestyle modifications, and followup of all patients receiving glucocorticoid therapy. The 17 recommendations concerning counseling for lifestyle modifications and followup of patients receiving glucocorticoids are shown in Tables 2 and 3. In addition to the recommendations listed, using the smallest dose of glucocorticoid for the shortest duration possible was recommended as an important strategy to minimize osteoporosis risk. Since there may be no dose of glucocorticoids that does not accelerate bone loss or increase fracture risk (3), recommendations for counseling and assessment are extended to all doses of glucocorticoids used or expected to be used for at least 3 months.

The panel recommended that an assessment of fall risk could include asking patients about previous falls and observing their gait. A variety of other approaches to fall risk evaluation are also available (92,93). The panel rec-

Table 2. Recommendations on counseling for lifestyle modification and assessment of patients starting glucocorticoids at any dose with an anticipated duration ≥ 3 months

Recommendation	Level of evidence
Weight-bearing activities	C
Smoking cessation	C
Avoidance of excessive alcohol intake (>2 drinks per day)	C
Nutritional counseling on calcium and vitamin D intake	C
Fall risk assessment	C
Baseline dual x-ray absorptiometry	C
Serum 25-hydroxyvitamin D level	C
Baseline height	C
Assessment of prevalent fragility fractures	C
Consider radiographic imaging of the spine or vertebral fracture assessment for those initiating or currently receiving prednisone ≥ 5 mg/day or its equivalent	C
Calcium intake (supplement plus oral intake) 1,200–1,500 mg/day*	A
Vitamin D supplementation*	A

* Recommendations for calcium and vitamin D supplementation are for any dose or duration of glucocorticoids, rather than a duration of >3 months.

ommended that clinicians consider vertebral fracture assessment (VFA), especially in the setting of significant height loss or a history of back pain consistent with a fracture, or conventional spine imaging because vertebral fractures are often asymptomatic, and might change treatment recommendations for patients receiving steroids who would otherwise be considered a low or medium risk (94,95). While grade 2 and 3 vertebral fractures classified according to the Genant semiquantitative method (96) have been shown to have high specificity for vertebral fracture, the panel noted that more research is needed to improve the specificity of grade 1 fractures noted on vertebral fracture assessment.

Calcium and vitamin D supplementation counseling was recommended for all patients beginning glucocorticoid therapy. Vitamin D supplementation to achieve “therapeutic” levels of 25-hydroxyvitamin D, or dosages of

Table 3. Recommended monitoring for patients receiving prevalent glucocorticoid therapy for a duration of ≥ 3 months

Recommendation	Level of evidence
Consider serial bone mineral density testing	C
Consider annual serum 25-hydroxyvitamin D measurement	C
Annual height measurement	C
Assessment of incident fragility fracture	C
Assessment of osteoporosis medication compliance	C

Table 4. Pharmacologic recommendations for postmenopausal women and men age ≥ 50 years starting glucocorticoid therapy with an anticipated duration of ≥ 3 months, or prevalent glucocorticoid therapy of a duration of at least 3 months (unless otherwise noted)

Recommendations	Level of evidence
Low-risk patient	
Alendronate for ≥ 7.5 mg/day prednisone	A
OR	
Risedronate for ≥ 7.5 mg/day prednisone	A
OR	
Zoledronic acid for ≥ 7.5 mg/day prednisone*	B
Medium-risk patient	
Alendronate for any dose of glucocorticoids	A
OR	
Risedronate for any dose of glucocorticoids	A
OR	
Zoledronic acid for ≥ 7.5 mg/day prednisone*	B
High-risk patient†	
Alendronate	A
OR	
Risedronate	A
OR	
Zoledronic acid*	B
OR	
Teriparatide‡	B

* Head-to-head comparison data available in the Discussion section.
 † Any anticipated dose or duration of glucocorticoids justifies initiating prescription therapy for high-risk patients.
 ‡ For ≥ 5 mg/day prednisone with a duration ≤ 1 month and for any dose of glucocorticoids with a duration >1 month. Head-to-head comparison data available in the Discussion section.

800–1,000 IU/day are 2 target dosing regimens; however, glucocorticoids can interfere with vitamin D absorption and may necessitate a higher supplementation dose to achieve therapeutic levels (97). Although serial bone density testing was recommended, the interval of such testing remains controversial (98,99). Factors that will influence the frequency of testing include the presence of additional risk factors for fracture, whether or not osteoporosis therapy has already been initiated, the results of the previous BMD, the dose of steroids, and the rate of change of the BMD.

Recommendations for low- and medium-risk postmenopausal glucocorticoid-treated women and glucocorticoid-treated men age ≥ 50 years. The recommendations for low- and medium-risk patients, as shown in Table 4, were to start prescription osteoporosis therapy for patients with an anticipated glucocorticoid usage duration of ≥ 3 months or those on prevalent glucocorticoid therapy for at least 3 months. The glucocorticoid dose warranting therapeutic intervention represents the practitioner’s intended average daily dose and varies according to the specific medication being considered.

Recommendations for high-risk postmenopausal glucocorticoid-treated women and glucocorticoid-treated men age ≥ 50 years. Consistent with the National Osteoporosis Foundation Guidelines (19) that suggest treatment

when the 10-year risk of major osteoporotic fractures is $\geq 20\%$ (our high-risk group), the Task Force Panel recommended that these patients receive prescription osteoporosis therapy even in the absence of glucocorticoid use, hence the recommendations for a duration of glucocorticoids of <1 month (Table 4).

Recommendations for premenopausal women and men age <50 years. Men younger than age 50 years were considered together with the premenopausal women. These 2 populations were thought to represent a similar patient group, insofar as there is limited evidence for the treatment of GIOP in both these populations. Furthermore, the risk factors that influence fracture propensity in these populations have not been well defined. The FRAX tool is currently not applicable to premenopausal women or men younger than age 40 years. Additionally, the long-term safety of medications used to treat GIOP in this population, and the risk of these medications to a fetus, either from current or previous exposure, is not well defined. For these reasons, the panel concluded that they could make recommendations only for those with a prevalent fragility fracture who were clearly at higher risk for additional fracture. For women of childbearing potential, drugs with shorter half-lives were recommended (as shown in Table 5). For those of nonchildbearing potential, the recommendations were similar to those for postmenopausal women and for men except that the anticipated duration of glucocorticoids required to trigger therapy was 3 months. The panel suggested this area warranted further research.

DISCUSSION

Developed using state-of-the-art validated methodology for guideline development, this report provides the updated ACR recommendations for adult patients receiving oral glucocorticoid therapy. The 2001 recommendations included counseling those patients receiving glucocorticoid therapy on smoking cessation or avoidance, limiting excessive alcohol intake, weight-bearing activities, calcium and vitamin D intake and supplementation, and obtaining baseline and followup BMD measurement. Recommendations for counseling and monitoring are now expanded to include fall risk assessment, height and 25-hydroxyvitamin D measurement, evaluation for prevalent and incident fragility fractures, and consideration for vertebral fracture assessment or radiographic imaging of the spine and calcium and vitamin D supplementation for any duration of glucocorticoid use. Updated pharmacologic recommendations are delineated for postmenopausal women and men over age 50 years, premenopausal women not of childbearing potential and men under the age of 50 years with a history of a fragility fracture, and premenopausal women of childbearing potential with a history of a fragility fracture. The newer therapies zoledronic acid and teriparatide are now recommended along with alendronate and risedronate for the treatment of GIOP, while the previously included therapies estrogen replacement and testosterone are no longer endorsed. Since BMD may not be as consistent a risk factor for fracture in GIOP when com-

Table 5. Recommendations for premenopausal women and men under age 50 years with a history of fragility fracture

	Grade of recommendation
1–3 MONTHS OF GLUCOCORTICOIDS	
Nonchildbearing potential	
Alendronate if receiving prednisone ≥ 5 mg/day	A
OR	
Risedronate if receiving prednisone ≥ 5 mg/day	A
OR	
Zoledronic acid if receiving prednisone ≥ 7.5 mg/day*	B
Childbearing potential—Inadequate data for recommendation	
≥ 3 MONTHS OF GLUCOCORTICOIDS	
Nonchildbearing potential	
Alendronate for any dose	A
OR	
Risedronate for any dose	A
OR	
Zoledronic acid for any dose*	B
OR	
Teriparatide for any dose*	B
Childbearing potential	
Alendronate if prednisone ≥ 7.5 mg/day	A
OR	
Risedronate if prednisone ≥ 7.5 mg/day	C
OR	
Teriparatide if prednisone ≥ 7.5 mg/day*	C
* Head-to-head comparison data available in the Discussion section.	

pared with other forms of osteoporosis (6), these recommendations are guided in part by the FRAX score or patients' overall clinical risk profiles. This represents an advance over previous recommendations, which relied on T scores.

While these recommendations improve upon previous statements, they are not without their limitations. The categorization of high, medium, and low risk for fracture assessment of patients is based largely on the FRAX tool (21), and there are limitations to FRAX that are important to consider. Several of the clinical risk factors contributing to FRAX do not take into account dose response but use "average" dose or exposure. However, there is good evidence that the risk associated with alcohol consumption and glucocorticoid use is dose related. Also, the computer modeling underlying FRAX uses only the bone density value for the hip, and this may be an issue in GIOP, since patients receiving glucocorticoids frequently lose bone mass in the spine before the hip, leading to a possible underestimation of fracture risk. Thus, FRAX alone cannot replace clinical judgment in risk stratification. Furthermore, based on the iterative formal group process, these

updated recommendations have added a greater number of thresholds around glucocorticoid dosing, reflecting the populations studied in clinical trials and the differing risk–benefit values of the agents. While the recommendations support the use of a variety of therapies, all medications have their own risk profiles (reviewed in the evidence report available in the Supplementary Appendix, which is available in the online version of this article at [http://onlinelibrary.wiley.com/journal/10.1002/\(ISSN\)2151-4658](http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2151-4658)) that need to be considered when evaluating individuals. Furthermore, every set of recommendations is limited by the quality of the available evidence, and in many situations additional clinical judgment will influence the application of these proposed recommendations.

The Task Force Panel discussed the incremental impact of various rheumatic diseases such as rheumatoid arthritis on GIOP risk and concluded that there was insufficient evidence to make disease-specific recommendations. Furthermore, this panel discussed the use of osteoporosis therapies for patients with chronic renal insufficiency and a creatinine clearance level <30 mg/minute. The panel did not reach a consensus in this population due to limited evidence, but concluded that there were certain circumstances in which therapeutic intervention should be considered for these patients, noting that these decisions should be individualized (100). Guidelines exist for the management of calcium, vitamin D, and phosphorus in patients with chronic renal insufficiency (101), and these areas were not specifically considered by the panels. Additionally, very little literature exists regarding the risk of and treatment for patients who receive intermittent pulse or intramuscular glucocorticoids without daily oral doses, and this population was not addressed in these recommendations.

The recommendations for premenopausal women and younger men are constrained by the paucity of evidence for fracture risk and the treatment of GIOP in this population. Low bone density in premenopausal patients has been associated with a lower fracture risk when compared with the same BMD in postmenopausal patients (102). However, some data also suggest that premenopausal patients receiving high-dose glucocorticoids may experience fracture at higher BMD than postmenopausal patients (103). Additionally, the majority of RCTs (with the exception of 4 that were limited to premenopausal patients) (30,33,42,44) include small proportions of premenopausal women (7–22% of the total population), thereby restricting the conclusions that can be drawn (7–9,11,12). The absence of specific recommendations should not be construed as counseling against treatment for premenopausal women and young male patients, but as an indication of the need for further research.

Despite the fact that some limited data address their efficacy in GIOP (31,50,73,83,84), the amount and quality of the data were considered insufficient for the panel to recommend the use of the following agents: ibandronate, etidronate, calcitonin, estrogen, testosterone, and raloxifene. Additionally, while these recommendations do not rate one drug as preferential over others, there are 2 recent active comparator studies of GIOP therapies. In an 18-

month study with additional 36-month data, teriparatide (20 µg/day) was more effective than alendronate (10 mg/day) at improving spine and hip BMD and reducing the risk of new vertebral fractures (11,104). In a 1-year trial, intravenous zoledronic acid (once yearly) was compared with risedronate (5 mg/day) (12). At 12 months, both treatment arms showed improvement in BMD; however, the BMD in the patients receiving zoledronic acid rose significantly more than in the patients receiving risedronate at both the lumbar spine and femoral neck. The vertebral fracture rates were low and did not differ between the 2 arms.

Glucocorticoid-induced osteoporosis is an undertreated condition. With more than an estimated 1 million patients in the US receiving a prescription for glucocorticoids yearly (16), GIOP has wide-reaching consequences. The goal of these recommendations is to improve awareness and increase the rate of counseling and treatment of GIOP. Despite significant advances in the understanding of the epidemiology of GIOP and despite an increased number of higher-quality clinical trials in recent years, gaps in knowledge still exist. It is anticipated that GIOP recommendations will undergo future revisions as new evidence is developed, which will further the aim of improving care for patients treated with glucocorticoids.

Addendum. Therapies that were approved after the original literature review are not included in these recommendations.

AUTHOR CONTRIBUTIONS

All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be submitted for publication. Dr. Grossman had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study conception and design. Grossman, Ranganath, Deal, Caplan, Chen, Curtis, Furst, McMahon, Patkar, Volkmann, Saag.

Acquisition of data. Grossman, Gordon, Ranganath, Deal, Caplan, Chen, Curtis, McMahon, Patkar, Volkmann, Saag.

Analysis and interpretation of data. Grossman, Gordon, Deal, Caplan, Chen, Curtis, Furst, McMahon, Patkar, Saag.

REFERENCES

1. Lane NE, Lukert B. The science and therapy of glucocorticoid-induced bone loss. *Endocrinol Metab Clin North Am* 1998;27:465–83.
2. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. *Rheumatology (Oxford)* 2000;39:1383–9.
3. Van Staa TP, Geusens P, Pols HA, de Laet C, Leufkens HG, Cooper C. A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. *QJM* 2005;98:191–8.
4. Sambrook PN, Eisman JA, Yeates MG, Popck NA, Eberl S, Champion GD. Osteoporosis in rheumatoid arthritis: safety of low dose corticosteroids. *Ann Rheum Dis* 1986;45:950–3.
5. Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM. Effects of low dose corticosteroids on the bone mineral density of patients with rheumatoid arthritis. *J Rheumatol* 1995;22:1055–9.
6. Kanis JA, Johansson H, Oden A, Johnell O, de Laet C, Melton LJ III, et al. A meta-analysis of prior corticosteroid use and fracture risk. *J Bone Miner Res* 2004;19:893–9.

7. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, et al. and the Glucocorticoid-Induced Osteoporosis Intervention Study Group. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. *N Engl J Med* 1998;339:292–9.
8. Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. *Arthritis Rheum* 1999;42:2309–18.
9. Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. *European Corticosteroid-Induced Osteoporosis Treatment Study*. *J Bone Miner Res* 2000;15:1006–13.
10. Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. *Calcif Tissue Int* 2000;67:277–85.
11. Saag KG, Shane E, Boonen S, Marin F, Donley DW, Taylor KA, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. *N Engl J Med* 2007;357:2028–39.
12. Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. *Lancet* 2009;373:1253–63.
13. Guzman-Clark JR, Fang MA, Sehl ME, Traylor L, Hahn TJ. Barriers in the management of glucocorticoid-induced osteoporosis. *Arthritis Rheum* 2007;57:140–6.
14. Curtis JR, Westfall AO, Allison JJ, Becker A, Casebeer L, Freeman A, et al. Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. *Arthritis Rheum* 2005;52:2485–94.
15. Solomon DH, Katz JN, Jacobs JP, La Tourette AM, Coblyn J. Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheumatology practice. *Arthritis Rheum* 2002;46:3136–42.
16. Feldstein AC, Elmer PJ, Nichols GA, Herson M. Practice patterns in patients at risk for glucocorticoid-induced osteoporosis. *Osteoporos Int* 2005;16:2168–74.
17. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. *Arthritis Rheum* 2001;44:1496–503.
18. FRAX. WHO Fracture Risk Assessment Tool. URL: <http://www.shef.ac.uk/FRAX/>.
19. National Osteoporosis Foundation. Clinician's guide to the prevention and treatment of osteoporosis. Washington (DC): National Osteoporosis Foundation; 2008.
20. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. *Arthritis Rheum* 2008;59:762–84.
21. Kanis JA, Oden A, Johansson H, Borgstrom F, Strom O, McCloskey E. FRAX and its applications to clinical practice. *Bone* 2009;44:734–43.
22. Dawson-Hughes B, Tosteson AN, Melton LJ III, Baim S, Favus MJ, Khosla S, et al. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. *Osteoporos Int* 2008;19:449–58.
23. Cheng H, Gary LC, Curtis JR, Saag KG, Kilgore ML, Morrissy MA, et al. Estimated prevalence and patterns of presumed osteoporosis among older Americans based on Medicare data. *Osteoporos Int* 2009;20:1507–15.
24. Barrett-Connor E, Siris ES, Wehren LE, Miller PD, Abbott TA, Berger ML, et al. Osteoporosis and fracture risk in women of different ethnic groups. *J Bone Miner Res* 2005;20:185–94.
25. Bultink IE, Lems WF, Kostense PJ, Dijkmans BA, Voskuyl AE. Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. *Arthritis Rheum* 2005;52:2044–50.
26. Dovic A, Perazzolo L, Osella G, Ventura M, Termine A, Milano E, et al. Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis. *J Clin Endocrinol Metab* 2004;89:4923–8.
27. MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttrop M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. *Ann Intern Med* 2008;148:197–213.
28. Lefebvre C, Eisinga A, McDonald S, Paul N. Enhancing access to reports of randomized trials published world-wide: the contribution of EMBASE records to the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library. *Emerg Themes Epidemiol* 2008;5:13.
29. Adachi JD, Bensen WG, Bianchi F, Cividino A, Pillersdorf S, Sebaldt RJ, et al. Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup. *J Rheumatol* 1996;23:995–1000.
30. Bernstein CN, Seeger LL, Anton PA, Artinian L, Geffrey S, Goodman W, et al. A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study. *Aliment Pharmacol Ther* 1996;10:777–86.
31. Kung AW, Chan TM, Lau CS, Wong RW, Yeung SS. Osteopenia in young hypogonadal women with systemic lupus erythematosus receiving chronic steroid therapy: a randomized controlled trial comparing calcitriol and hormonal replacement therapy. *Rheumatology (Oxford)* 1999;38:1239–44.
32. Lakatos P, Nagy Z, Kiss L, Horvath C, Takacs I, Foldes J, et al. Prevention of corticosteroid-induced osteoporosis by alfacalcidol. *Z Rheumatol* 2000;59 Suppl 1:48–52.
33. Lambrinouadaki I, Chan DT, Lau CS, Wong RW, Yeung SS, Kung AW. Effect of calcitriol on bone mineral density in premenopausal Chinese women taking chronic steroid therapy: a randomized, double blind, placebo controlled study. *J Rheumatol* 2000;27:1759–65.
34. Gonnelli S, Rottoli P, Cepollaro C, Pondrelli C, Cappiello V, Vagliasindi M, et al. Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients. *Calcif Tissue Int* 1997;61:382–5.
35. McDonald CF, Zebaze RM, Seeman E. Calcitriol does not prevent bone loss in patients with asthma receiving corticosteroid therapy: a double-blind placebo-controlled trial. *Osteoporos Int* 2006;17:1546–51.
36. Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. *Arthritis Rheum* 2001;44:202–11.
37. Yilmaz L, Ozoran K, Gunduz OH, Ucan H, Yucel M. Alendronate in rheumatoid arthritis patients treated with methotrexate and glucocorticoids. *Rheumatol Int* 2001;20:65–9.
38. Lems WF, Lodder MC, Lips P, Bijlsma JW, Geusens P, Schrameijer N, et al. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial. *Osteoporos Int* 2006;17:716–23.
39. Sambrook PN, Kotowicz M, Nash P, Styles CB, Naganathan V, Henderson-Briffa KN, et al. Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. *J Bone Miner Res* 2003;18:919–24.
40. Tascioglu F, Colak O, Armagan O, Alatas O, Oner C. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin. *Rheumatol Int* 2005;26:21–9.
41. De Nijs RN, Jacobs JW, Lems WF, Laan RF, Algra A, Huisman

- AM, et al. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. *N Engl J Med* 2006;355:675–84.
42. Okada Y, Nawata M, Nakayamada S, Saito K, Tanaka Y. Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapy. *J Rheumatol* 2008;35:2249–54.
 43. Takeda S, Kaneoka H, Saito T. Effect of alendronate on glucocorticoid-induced osteoporosis in Japanese women with systemic autoimmune diseases: versus alfacalcidol. *Mod Rheumatol* 2008;18:271–6.
 44. Yeap SS, Fauzi AR, Kong NC, Halim AG, Soehardy Z, Rahimah I, et al. A comparison of calcium, calcitriol, and alendronate in corticosteroid-treated premenopausal patients with systemic lupus erythematosus. *J Rheumatol* 2008;35:2344–7.
 45. Kikuchi Y, Imakiire T, Yamada M, Saigusa T, Hyodo T, Kushiyama T, et al. Effect of risedronate on high-dose corticosteroid-induced bone loss in patients with glomerular disease. *Nephrol Dial Transplant* 2007;22:1593–600.
 46. Fujii N, Hamano T, Mikami S, Nagasawa Y, Isaka Y, Moriyama T, et al. Risedronate, an effective treatment for glucocorticoid-induced bone loss in CKD patients with or without concomitant active vitamin D (PRIUS-CKD). *Nephrol Dial Transplant* 2007;22:1601–7.
 47. Mok CC, Tong KH, To CH, Siu YP, Ma KM. Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial. *Osteoporos Int* 2008;19:357–64.
 48. Yamada S, Takagi H, Tsuchiya H, Nakajima T, Ochiai H, Ichimura A, et al. Comparative studies on effect of risedronate and alfacalcidol against glucocorticoid-induced osteoporosis in rheumatoid arthritic patients. *Yakugaku Zasshi* 2007;127:1491–6.
 49. Ringe JD, Dorst A, Faber H, Ibach K, Sorenson F. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. *Osteoporos Int* 2003;14:801–7.
 50. Ringe JD, Dorst A, Faber H, Ibach K, Preuss J. Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis. *Rheumatology (Oxford)* 2003;42:743–9.
 51. Struys A, Snelder AA, Mulder H. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. *Am J Med* 1995;99:235–42.
 52. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. *N Engl J Med* 1997;337:382–7.
 53. Mulder H, Struys A. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. *Br J Rheumatol* 1994;33:348–50.
 54. Wolfhagen FH, van Buuren HR, den Ouden JW, Hop WC, van Leeuwen JP, Schalm SW, et al. Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis: a prospective, controlled pilot study. *J Hepatol* 1997;26:325–30.
 55. Pitt P, Li F, Todd P, Webber D, Pack S, Moniz C. A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term oral corticosteroid treatment. *Thorax* 1998;53:351–6.
 56. Roux C, Oriente P, Laan R, Hughes RA, Ittner J, Goemaere S, et al, and the Ciblos Study Group. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. *J Clin Endocrinol Metab* 1998;83:1128–33.
 57. Skingle SJ, Moore DJ, Crisp AJ. Cyclical etidronate increases lumbar spine bone density in patients on long-term glucocorticosteroid therapy. *Int J Clin Pract* 1997;51:364–7.
 58. Cortet B, Hachulla E, Barton I, Bonvoisin B, Roux C. Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid-induced bone loss in patients with inflammatory rheumatic diseases: a randomized study. *Rev Rhum Engl Ed* 1999;66:214–9.
 59. Geusens P, Dequeker J, Vanhoof J, Stalmans R, Boonen S, Joly J, et al. Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment: a double blind, randomised placebo controlled study. *Ann Rheum Dis* 1998;57:724–7.
 60. Jenkins EA, Walker-Bone KE, Wood A, McCrae FC, Cooper C, Cawley MI. The prevention of corticosteroid-induced bone loss with intermittent cyclical etidronate. *Scand J Rheumatol* 1999;28:152–6.
 61. Jinnouchi Y. Efficacy of intermittent etidronate therapy for corticosteroid-induced osteoporosis in patients with diffuse connective tissue disease. *Kurume Med J* 2000;47:219–24.
 62. Nakayamada S, Okada Y, Saito K, Tanaka Y. Etidronate prevents high dose glucocorticoid induced bone loss in premenopausal individuals with systemic autoimmune diseases. *J Rheumatol* 2004;31:163–6.
 63. Sato S, Ohosone Y, Suwa A, Yasuoka H, Nojima T, Fujii T, et al. Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year followup. *J Rheumatol* 2003;30:2673–9.
 64. Sato S, Takada T, Katsuki Y, Kimura N, Kaneko Y, Suwa A, et al. Longterm effect of intermittent cyclical etidronate therapy on corticosteroid-induced osteoporosis in Japanese patients with connective tissue disease: 7-year followup. *J Rheumatol* 2008;35:142–6.
 65. Campbell IA, Douglas JG, Francis RM, Prescott RJ, Reid DM. Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoids. *Thorax* 2004;59:761–8.
 66. Ortego-Centeno N, Munoz-Torres M, Callejas-Rubio JL, Rivera-Montes M. Etidronate and glucocorticoid induced osteoporosis [letter]. *J Rheumatol* 2005;32:199–200.
 67. Sambrook P, Birmingham J, Kelly P, Kempler S, Nguyen T, Pocock N, et al. Prevention of corticosteroid osteoporosis: a comparison of calcium, calcitriol, and calcitonin. *N Engl J Med* 1993;328:1747–52.
 68. Kotaniemi A, Piirainen H, Paimela L, Leirisalo-Repo M, Uoti-Reilama K, Lahdentausta P, et al. Is continuous intranasal salmon calcitonin effective in treating axial bone loss in patients with active rheumatoid arthritis receiving low dose glucocorticoid therapy? *J Rheumatol* 1996;23:1875–9.
 69. Luengo M, Pons F, Martinez de Osaba MJ, Picado C. Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: a two year follow up study. *Thorax* 1994;49:1099–102.
 70. Adachi JD, Bensen WG, Bell MJ, Bianchi FA, Cividino AA, Craig GL, et al. Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis. *Br J Rheumatol* 1997;36:255–9.
 71. Healey JH, Paget SA, Williams-Russo P, Szatrowski TP, Schneider R, Spiera H, et al. A randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica. *Calcif Tissue Int* 1996;58:73–80.
 72. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis: results of a randomized controlled clinical trial. *J Clin Invest* 1998;102:1627–33.
 73. Mok CC, To CH, Mak A, Ma KM. Raloxifene for postmenopausal women with systemic lupus erythematosus: a pilot randomized controlled study. *Arthritis Rheum* 2005;52:3997–4002.
 74. Reid IR, Wattie DJ, Evans MC, Stapleton JP. Testosterone therapy in glucocorticoid-treated men. *Arch Intern Med* 1996;156:1173–7.
 75. Ozoran K, Yildirim M, Onder M, Sivas F, Inanir A. The bone mineral density effects of calcitonin and alendronate combined therapy in patient with rheumatoid arthritis. *APLAR J Rheumatol* 2007;10:17–22.
 76. Ringe JD, Dorst A, Faber H, Schacht E, Rahlfs VW. Superi-

- ority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis. *Rheumatol Int* 2004; 24:63–70.
77. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? *Control Clin Trials* 1996;17:1–12.
 78. Homik J, Cranney A, Shea B, Tugwell P, Wells G, Adachi R, et al. Bisphosphonates for steroid induced osteoporosis. *Cochrane Database Syst Rev* 2000;2:CD001347.
 79. Homik J, Suarez-Almazor ME, Shea B, Cranney A, Wells G, Tugwell P. Calcium and vitamin D for corticosteroid-induced osteoporosis. *Cochrane Database Syst Rev* 2000;2:CD000952.
 80. Homik JE, Cranney A, Shea B, Tugwell P, Wells G, Adachi JD, et al. A metaanalysis on the use of bisphosphonates in corticosteroid induced osteoporosis. *J Rheumatol* 1999;26: 1148–57.
 81. De Nijs RN, Jacobs JW, Algra A, Lems WF, Bijlsma JW. Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies. *Osteoporos Int* 2004;15:589–602.
 82. Amin S, LaValley MP, Simms RW, Felson DT. The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach. *Arthritis Rheum* 1999;42:1740–51.
 83. Adachi JD, Roux C, Pitt PI, Cooper C, Moniz C, Dequeker J, et al. A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss. *J Rheumatol* 2000;27:2424–31.
 84. Cranney A, Welch V, Adachi JD, Homik J, Shea B, Suarez-Almazor ME, et al. Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis. *Cochrane Database Syst Rev* 2000;2:CD001983.
 85. McGory ML, Shekelle PG, Rubenstein LZ, Fink A, Ko CY. Developing quality indicators for elderly patients undergoing abdominal operations. *J Am Coll Surg* 2005;201:870–83.
 86. Shekelle P. The appropriateness method. *Med Decis Making* 2004;24:228–31.
 87. Shekelle PG, Park RE, Kahan JP, Leape LL, Kamberg CJ, Bernstein SJ. Sensitivity and specificity of the RAND/UCLA Appropriateness Method to identify the overuse and underuse of coronary revascularization and hysterectomy. *J Clin Epidemiol* 2001;54:1004–10.
 88. Campbell SM, Hann M, Hacker J, Durie A, Thapar A, Roland MO. Quality assessment for three common conditions in primary care: validity and reliability of review criteria developed by expert panels for angina, asthma and type 2 diabetes. *Qual Saf Health Care* 2002;11:125–30.
 89. Shekelle PG, Kahan JP, Bernstein SJ, Leape LL, Kamberg CJ, Park RE. The reproducibility of a method to identify the overuse and underuse of medical procedures. *N Engl J Med* 1998;338:1888–95.
 90. Vlayen J, Aertgeerts B, Hannes K, Sermeus W, Ramaekers D. A systematic review of appraisal tools for clinical practice guidelines: multiple similarities and one common deficit. *Int J Qual Health Care* 2005;17:235–42.
 91. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to update the 2001 guidelines for the evaluation and management of heart failure). Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. *Circulation* 2005;112:e154–235.
 92. Gillespie LD, Robertson MC, Gillespie WJ, Lamb SE, Gates S, Cumming RG, et al. Interventions for preventing falls in older people living in the community. *Cochrane Database Syst Rev* 2009;2:CD007146.
 93. Ganz DA, Bao Y, Shekelle PG, Rubenstein LZ. Will my patient fall? *JAMA* 2007;297:77–86.
 94. Schousboe JT, Vokes T, Broy SB, Ferrar L, McKiernan F, Roux C, et al. Vertebral fracture assessment: the 2007 ISCD official positions. *J Clin Densitom* 2008;11:92–108.
 95. Lewiecki EM, Laster AJ. Clinical review: clinical applications of vertebral fracture assessment by dual-energy x-ray absorptiometry. *J Clin Endocrinol Metab* 2006;91:4215–22.
 96. Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. *J Bone Miner Res* 1993;8:1137–48.
 97. Holick MF. Optimal vitamin D status for the prevention and treatment of osteoporosis. *Drugs Aging* 2007;24:1017–29.
 98. Watts NB, Lewiecki EM, Bonnick SL, Laster AJ, Binkley N, Blank RD, et al. Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis. *J Bone Miner Res* 2009;24:1643–6.
 99. Bell KJ, Hayen A, Macaskill P, Irwig L, Craig JC, Ensrud K, et al. Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data. *BMJ* 2009;338:b2266.
 100. Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. *J Bone Miner Res* 2005;20:2105–15.
 101. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. *Am J Kidney Dis* 2003;42 Suppl 3:S1–201.
 102. Cohen A, Shane E. Treatment of premenopausal women with low bone mineral density. *Curr Osteoporos Rep* 2008; 6:39–46.
 103. Kumagai S, Kawano S, Atsumi T, Inokuma S, Okada Y, Kanai Y, et al. Vertebral fracture and bone mineral density in women receiving high dose glucocorticoids for treatment of autoimmune diseases. *J Rheumatol* 2005;32:863–9.
 104. Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. *Arthritis Rheum* 2009;60:3346–55.